BioXcel Therapeutics (BTAI) Enterprise Value (2017 - 2026)

BioXcel Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$17.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 44.6% year-over-year to -$17.2 million in Q1 2026; TTM through Mar 2026 was -$17.2 million, a 44.6% increase from a year earlier, with the FY2025 full-year figure at -$28.8 million, up 3.67% from the prior year.
• Enterprise Value rose to -$17.2 million in Q1 2026 per BTAI's latest filing, from -$28.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$17.2 million in Q1 2026 and bottomed at -$233.5 million in Q2 2022.
• The 5-year median for Enterprise Value is -$65.2 million (2023), against an average of -$96.6 million.
• Across the five-year window, Enterprise Value dropped 3.31% in 2022 and jumped 66.99% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$193.7 million in 2022, then soared by 66.33% to -$65.2 million in 2023, then jumped by 54.23% to -$29.9 million in 2024, then increased by 3.67% to -$28.8 million in 2025, then soared by 40.26% to -$17.2 million in 2026.
• Per Business Quant, the three latest BTAI Enterprise Value figures stand at -$17.2 million (Q1 2026), -$28.8 million (Q4 2025), and -$37.3 million (Q3 2025).